Combinations of cancer drugs can be quickly and cheaply tested on tumour cells using a novel device developed by EMBL scientists. The research, reported in Nature Communications on June 22, marks the latest advancement in the field of personalised medicine.
Using a microfluidic device that fits in the palm of your hand, scientists screened over 1100 treatment conditions (56 drug combinations x 20 replicates) on patient tumour cells. In the future, such tests could be used to inform clinicians on safe and effective combinations of cancer treatments. This research, incorporating fundamental science alongside clinical expertise at Aachen University Hospital, was led by EMBL group leader Christoph Merten and Julio Saez-Rodriguez, former group leader at EMBL-EBI and now Professor at Heidelberg University.
Small biopsies, many drugs
Directly testing multiple cancer drugs on biopsies – parts of the tumour which have been taken from a patient – is a powerful way to discover which drugs work best, and for whom. This is because depending on the specific tumour characteristics, cancer therapies can be more effective in some people than others. However, large-scale patient specific drug screenings have so far been limited by the small biopsy size that can typically be obtained from patients. That is why in the current paper, the team developed a miniaturised device which can test more drugs on a limited number of cells.
The research team initially tested 56 drug combinations on two different human cancer cell types grown in the lab. Drug combinations which killed both types of cancer cells were thought to be potentially toxic and thus unsafe for further testing. However, some drug combinations which targeted and killed only one type of cancer cell were found to be more effective than standard clinical therapies which only use one drug. These results were highly reproducible and could be validated in mouse models of human cancer.
Subsequently, cells from four cancer patient biopsies were applied to the microfluidic device and different drug combinations were tested. “We found that each individual cancer responded best to a different combination of drugs, highlighting the urgent need for patient-specific therapies,” says Federica Eduati, joint first author on the paper alongside Ramesh Utharala who designed and developed the microfluidic device.
“Before we transfer this technology into the clinics, we need to repeat these experiments in larger-scale mouse studies to understand which types of cancer this technology works best in,” says Christoph Merten. “Still, this is an exciting ‘proof of principle’ collaboration between scientists and clinicians, and we have shown that these tests can be run quickly and for less than $150 USD per patient.”
Receive an email update when we add a new PERSONALIZED MEDICINE article.
The Latest on: Personalized medicine
via Google News
The Latest on: Personalized medicine
- Viewpoint: The problem with personalized medicine is that ‘statistics are being misinterpreted’ on December 14, 2018 at 5:16 am
Personalized medicine aims to match individuals with the therapy that is best suited to them and their condition. Advocates proclaim the potential of this approach to improve treatment outcomes by ... […]
- Many Americans Unaware of Promise of Personalized Medicine on December 12, 2018 at 3:02 am
(HealthDay News) -- Medical science has made tremendous advances in personalized medicine. However, the American public is still struggling to understand the implications of these targeted treatments, ... […]
- Personalized Medicine Tool for Inherited Colorectal Cancer Syndrome Developed on December 11, 2018 at 12:47 pm
A novel tool for identifying the genetic changes in Lynch syndrome genes that are likely to be responsible for causing symptoms of the disease has been developed, calibrated and validated by an intern... […]
- Novel personalized medicine tool for assessing inherited colorectal cancer syndrome risk developed on December 10, 2018 at 11:15 am
An international team of researchers led by Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has developed, calibrated, and validated a novel tool for identifying the genetic changes ... […]
- Researchers develop personalized medicine tool for inherited colorectal cancer syndrome on December 10, 2018 at 9:40 am
Cancer — Histopathologic image of colonic carcinoid. Credit: Wikipedia/CC BY-SA 3.0 An international team of researchers led by Huntsman Cancer Institute (HCI) at the University of Utah (U of U ... […]
- Personalized medicine tool for inherited colorectal cancer syndrome on December 10, 2018 at 7:29 am
An international team of researchers has developed, calibrated, and validated a novel tool for identifying the genetic changes in Lynch syndrome genes that are likely to be responsible for causing ... […]
- Personalized Medicine Market Volume Analysis, Segments, Value Share and Key Trends on December 10, 2018 at 4:10 am
Personalized medicine are drugs that are based on individual patient or intended patient groups carrying certain biomarkers and are created to cater the requirement of an individual patient based on t... […]
- Personalized Medicine: A Potential Game Changer, Someday on December 6, 2018 at 8:06 am
There's a lot of talk about the potential for personalized medicine to lower drug costs. Genetic testing has been around for a few years, and it's being used to customize drug regimens for patients by ... […]
- Many Americans unaware of promise of targeted, 'personalized' medicine: poll on December 6, 2018 at 7:34 am
(HealthDay)—Medical science has made tremendous advances in "personalized medicine"—drugs that fight cancer and other diseases by boosting the immune system or targeting specific genetic traits. […]
via Bing News